logo
Quick Facts
  

Agilent Technologies To Repurchase Up To $2 Bln Of Stock

By RTTNews Staff Writer   ✉   | Published:

Agilent Technologies Inc. (A) said that its board has approved a new share
repurchase program. The 2023 program authorizes the purchase of up to $2
billion of the company's common stock. The new program will begin March 1.

The company noted that the new repurchase program replaces Agilent's existing stock repurchase program, which authorized the repurchase of shares to reduce or eliminate share dilution from equity programs.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's Neuralink Gets FDA Approval For Human Trials
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study!
T.W. Garner Food Recalls Texas Pete Buffalo Wing Sauce
T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6.
FDA Approves Pfizer's COVID-19 Pill Paxlovid
The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Latest Updates on COVID-19
Read More
COVID-19: Drugs in Development
Follow RTT
Copyright © 2023 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap